...
首页> 外文期刊>European journal of clinical microbiology and infectious diseases: Official publication of the European Society of Clinical Microbiology >Quality of molecular detection of vancomycin resistance in enterococci: results of 6 consecutive years of Quality Control for Molecular Diagnostics (QCMD) external quality assessment
【24h】

Quality of molecular detection of vancomycin resistance in enterococci: results of 6 consecutive years of Quality Control for Molecular Diagnostics (QCMD) external quality assessment

机译:肠球菌在肠球菌中抗性的分子检测质量:结果6年连续6年的质量控制用于分子诊断(QCMD)外部质量评估

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The quality of PCR to detect vancomycin-resistant enterococci (VRE) was evaluated by analysing their performance in six consecutive external quality assessment (EQA) schemes, organized annually since 2013 by Quality Control for Molecular Diagnostics. VRE EQA panels consisted of 12-14 heat-inactivated samples. Sensitivity was tested with vanA-positive Enterococcus faecium (E. faecium), vanB-positive E. faecium, E. faecalis or E. gallinarum or vanC-positive E. gallinarum in different concentrations. Vancomycin-susceptible enterococci, Staphylococcus aureus or sample matrix was used to study the specificity. Participants were asked to report the VRE resistance status of each sample. The detection rate of vanA-positive samples was already 95% in the 2013 EQA panel (range 94-97%) and remained stable over the years. The 2013 detection rate of vanB-positive samples was 82% but increased significantly by more than 10% in subsequent years (96% in 2014, 95% in 2015, 92% in 2016 and 93% in 2017/2018, p < 0.05). The vanC detection rate by the limited number of assays specifically targeting this gene was lower compared to vanA/B (range 55-89%). The number of false positives in the true-negative sample (8% in 2013 to 1.4% in 2018) as well as the van-gene-negative bacterial samples (4% in 2013 to 0% in 2018) declined over the years. In the six years of VRE proficiency testing to date, the detection of vanA-positive strains was excellent and an increased sensitivity in vanB detection as well as an increase in specificity was observed. Commercial and in-house assays performed equally well.
机译:通过分析其在连续六个外部质量评估(EQA)方案中的性能,通过分子诊断的质量控制来分析它们在每年组织的六种连续外部质量评估(EQA)方案的性能来评估PCR的质量。 VRE EQA面板由12-14个热灭活样品组成。用Vana阳性肠球菌(E. Faecium),VANB阳性大肠杆菌,E. FAPALIS或E. Ballinarum或Vanc阳性E. Ballinarum以不同浓度的敏感性。 Vancomycin-易感肠,金黄色葡萄球菌或样品基质用于研究特异性。要求参与者报告每个样本的阻力状态。 2013年EQA面板(范围为94-97%),Vana阳性样品的检出率已经是95%,多年来保持稳定。 2013年VANB阳性样品的检测率为82%,但随后几年(2014年96%96%,2015年95%,2016年92%的92%,2017年的升值量明显增长了10%,2017/2018年92%为92%,P <0.05) 。与Vana / B的特异性靶向该基因的有限测定的VANC检测率降低(范围55-89%)。真正消极样本中的误报的数量(2013年8%到2018年的1.4%)以及van-基因阴性细菌样本(2013年为4%到2018年的0%)多年来下降。在迄今为止迄今为止的六年的历史记录中,检测Vana阳性菌株的优异且VANB检测的敏感性增加以及观察到特异性的增加。商业和内部测定同样良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号